Stocks tried to stage a weak rally to close the week after the latest reading on inflation came in line with expectations. However, the longer-term direction for stocks may come down to whether ...

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $28.87, denoting a +0.7% change from the preceding trading day.

Zuckerberg is going all-in on AI, launching a dedicated Meta AI app to challenge OpenAI, Google, and Musk's xAI.

We recently published a list of 10 Worst Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are ...

Weight-loss drugs like Wegovy and Zepbound are proving incredibly lucrative, and analysts project this field will grow by leaps and bounds through the end of the decade. Viking Therapeutics is looking ...

The stock, which has tumbled more than 45% over the past year, could climb 87% within the coming 12 months, Wall Street ...

Global Retirement Partners LLC trimmed its stake in Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by 19.8% during the ...

State of New Jersey Common Pension Fund D boosted its stake in Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by 8.5% during the fourth quarter, according to its most recent Form 13F filing ...

However, there are many contenders in the works. One of the most promising GLP-1 contenders is VK2735, a dual GLP-1/GIP ...

Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) have been assigned a consensus rating of “Buy” from the fifteen brokerages that are covering the firm, Ratings reports. One equities ...

Viking Therapeutics (NASDAQ: VKTX) soared into the spotlight about a year ago when it delivered promising data on a drug ...

Viking advances VK2735 with a phase 2a study targeting results in H2'25. Phase 3 begins in Q2'25, fueling progress and ...